Pregabalin: Two hours preoperative patient will receive one capsule of Pregabalin 75 mg (Lyrica 75 mg, Viatris) and) and one placebo tablet and will continue on both of them twice daily for seven days postoperative
Pregabalin + Amantadine: Two hours preoperative patient will receive one capsule of pregabalin 75 mg (Lyrica 75 mg, Viatris) and one tablet of Amantadine 100 mg (PK-Merz 100 mg, MERZ Pharma) and will continue on both twice daily for seven days postoperative.
Pregabalin + Duloxetine: Two hours preoperative patient will receive one capsule of pregabalin 75 mg (Lyrica 75 mg, Viatris) and one capsule of Duloxetine 30 mg (Cymbatex 30 mg, EVA Pharma) and will continue on both twice daily for seven days postoperative.
Study summary
This study aims to evaluate the additive effect of Amantadine or Duloxetine to Pregabalin on development of post mastectomy pain syndrome
Eligibility
Sex
FEMALE
Min age
18 Years
Max age
65 Years
Healthy volunteers
No
Inclusion Criteria:
* Age from 18 to 65 years.
* American society of anesthesiologists (ASA) Physical status II, III.
* Body mass index (BMI): (20-40) kg/m2.
* Type of surgery: patients undergoing modified radical mastectomy for breast cancer.
Exclusion Criteria:
* Patient refusal.
* Patients with Known sensitivity or contraindication to drug used in the study.
* History of psychological disorders and/or chronic pain and drug abuse patients.
* Previous administration of antidepressants, anticonvulsants, or opioids before surgery.
* Severe respiratory or cardiac disorders.
* Advanced liver or kidney disease.
* Previous breast surgery
Primary outcome measure(s)
The rate of occurrence of post mastectomy pain syndrome — 12 weeks post-procedure The rate of occurrence of post mastectomy pain syndrome will be recorded according to Grading system for neuropathic pain (GSNP). GSNP is as follows: Grade 1 (unlikely), Grade 2 (possible), Grade 3 (probable), and Grade 4 (definite), the patients will be considered positive regarding incidence being in grade 3 or 4.
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.